Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25218063 | 0.79 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTL3MBTL1LMNA | |
| SCHEMBL25225086 | 0.79 | TSHR (0.61) | ALDH1A1KDM4EMAPTL3MBTL1LMNA | |
| SCHEMBL26248058 | 0.79 | TSHR (0.50) | ALDH1A1KDM4EMAPTL3MBTL1LMNA | |
| SCHEMBL22861877 | 0.78 | CYP1A2 (0.53) | — | |
| SCHEMBL8689559 | 0.76 | ALDH1A1 (0.62) | ALDH1A1KDM4EL3MBTL1LMNAKMT2A | |
| SCHEMBL11337833 | 0.74 | ALDH1A1 (0.67) | ALDH1A1THRBKDM4ELMNATSHR | |
| SCHEMBL11344104 | 0.73 | ALDH1A1 (0.68) | ALDH1A1THRBKDM4EMAPTL3MBTL1 | |
| SCHEMBL30585369 | 0.73 | — | — | |
| SCHEMBL25219425 | 0.73 | CYP1A2 (0.56) | ALDH1A1KDM4EMAPTTSHRKMT2A | |
| SCHEMBL897672 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702394-B2 | Inhibitors of phospholipid synthesis and methods of use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210002240-A1 | INHIBITORS OF PHOSPHOLIPID SYNTHESIS AND METHODS OF USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702394-B2 | Inhibitors of phospholipid synthesis and methods of use | LCAT, AGPAT2, GNPAT | ALDH1A1 2439/4885THRB 2349/4885KDM4E 2735/4885 |
| US-20210002240-A1 | INHIBITORS OF PHOSPHOLIPID SYNTHESIS AND METHODS OF USE | LCAT, AGPAT2, GNPAT | ALDH1A1 2439/4885THRB 2349/4885KDM4E 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.